Journal Article

DKFZ-2019-01840

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Lymph node involvement in treatment-naïve prostate cancer patients - correlation of PSMA-PET/CT imaging and Roach formula in 280 men in the Radiotherapeutic management.

Koerber, S. A. ; Stach, G. ; Kratochwil, C. ; Haefner, M. F. ; Rathke, H. ; Herfarth, K. ; Kopka, K.DKFZ* ; Holland-Letz, T.DKFZ* ; Choyke, P. L. ; Will, L. ; Haberkorn, U.DKFZ* ; Debus, J.DKFZ* ; Giesel, F. (Last author)DKFZ*

2020
Soc. New York, NY

This record in other databases:  

Please use a persistent id in citations: doi:10.2967/jnumed.119.227637

Abstract: The importance of PSMA-PET/CT for primary staging of treatment-naïve prostate cancer patients is still under debate. Therefore, the present study aimed to evaluate the role of PSMA PET/CT in detecting nodal metastases in a large cohort of men and compare imaging results with the risk of lymph node involvement based on the Roach formula. Methods: In total, 280 men with newly diagnosed prostate carcinoma were included in the present study. For all patients PSMA-PET/CT was performed for primary staging. Median age was 67 years (range 38 - 84 years), 84% of all patients were classified as high-risk according to d'Amico. The risk of lymph node involvement was calculated using the Roach formula and compared to the PSMA-PET/CT results. Results: PSMA-positive nodes were detected in 90 of 280 men (32.1%). While the majority of nodal metastases occurred within the pelvis, 35.5% were observed in extrapelvic sites. In 9 patients (3.2%), nodal metastases occurred in the Virchow node. After comparison of PSMA data with the results of the Roach formula, an area under the curve (AUC) of 0.781 was obtained for the Roach predictions. Conclusion: For treatment-naïve prostate cancer patients, PSMA-PET/CT is well suited for the detection of nodal metastases. However, the original Roach formula can still be used for a quick assessment of potential lymphatic spread in daily clinical routine.

Note: 2020 Jan;61(1):46-50#LA:E060#

---

Contributing Institute(s):

1. E060 KKE Nuklearmedizin (E060)
2. E030 Radiopharmazeutische Chemie (E030)
3. DKTK HD zentral (HD01)
4. C060 Biostatistik (C060)
5. E050 KKE Strahlentherapie (E050)

Research Program(s):

1. 315 - Imaging and radiooncology (POF3-315) (POF3-315)

Appears in the scientific report 2020

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---